About
OnTimeBio is developing a highly sensitive blood test to enable timely detection and monitoring of diseases. OnTimeBio's product utilizes advanced computational approaches with genomic and epigenomic approaches in order to enable a quantitative and exact readout of tissue dynamics across the organs of the human body. Applying the technology across multiple diseases, including cancer, metabolic, autoimmune, and neurodegenerative diseases, can reduce patient suffering and enable better treatment outcomes while lowering healthcare costs. For developers of novel therapeutics, the technology provides a lens to the body's response across all targeted tissues. This allows better patient stratification and precise and swift monitoring of patients' responses to new therapies.
Q&A
- What is OnTimeBio's primary focus?
- OnTimeBio is developing a highly sensitive blood test for the timely detection and monitoring of various diseases, including cancer, metabolic, autoimmune, and neurodegenerative diseases.
- When was OnTimeBio founded?
- OnTimeBio was founded in January 2017.
- Where is OnTimeBio headquartered?
- OnTimeBio is headquartered in Jerusalem, Jerusalem District, Israel.
- What is the current status of OnTimeBio?
- OnTimeBio is currently inactive, having ceased operations in November 2019.
- What is OnTimeBio's product stage?
- OnTimeBio's product is in the R&D stage.
- Who are the founders of OnTimeBio?
- The founders of OnTimeBio are Yuval Dor and Ariel Cohen.
- What business model does OnTimeBio use?
- OnTimeBio operates on a B2B business model.
Team · 2
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/18051725 |
Identifiers & details
| Founded | 2017-1 |
|---|---|
| Status reason | Non Active, Nov 2019 ceased to operate |